Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Federal Trade Commission
US Army
Chinese Patent Office
UBS
Harvard Business School
QuintilesIMS
Julphar
Colorcon
Mallinckrodt

Generated: October 16, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 040524

« Back to Dashboard
NDA 040524 describes PROMETHAZINE HYDROCHLORIDE, which is a drug marketed by Perrigo New York, Watson Labs, Taro, Ivax Sub Teva Pharms, Able, Teva, West-ward Pharms Int, Kvk Tech, Impax Labs, Pvt Form, Luitpold, Pharm Assoc, Abbott, Prinston Inc, Bedford Labs, Hi Tech Pharma, Tablicaps, G And W Labs, Sandoz, X-gen Pharms, Hospira, Vintage, Lannett, Teva Pharms Usa, Mylan, Sun Pharm Inds, Akorn, Marsam Pharms Llc, Sun Pharm Inds Inc, Mylan Institutional, Heritage Pharma, Tris Pharma Inc, Strides Pharma, Watson Labs Inc, Amneal Pharms Ny, Amneal Pharms, Wockhardt, Kv Pharm, Nostrum Labs Inc, Whiteworth Town Plsn, Zydus Pharms Usa, Actavis Mid Atlantic, Ani Pharms, and Hi-tech Pharma Co, and is included in eighty-seven NDAs. It is available from sixty-six suppliers. Additional details are available on the PROMETHAZINE HYDROCHLORIDE profile page.

The generic ingredient in PROMETHAZINE HYDROCHLORIDE is codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride. There are nineteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride profile page.

Summary for NDA: 040524

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antiemetics
Respiratory Tract Agents
Formulation / Manufacturing:see details

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength25MG/ML
Approval Date:Mar 17, 2004TE:RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength50MG/ML
Approval Date:Mar 17, 2004TE:RLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Healthtrust
Express Scripts
Moodys
McKinsey
Dow
Federal Trade Commission
Chubb
QuintilesIMS
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot